158 related articles for article (PubMed ID: 37950790)
21. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
Govoni M; Batalov A; Boumpas DT; D'Angelo S; De Keyser F; Flipo RM; Kellner H; Leroi H; Khalifa A
Clin Exp Rheumatol; 2024 Mar; 42(3):642-650. PubMed ID: 37976120
[TBL] [Abstract][Full Text] [Related]
22. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
Emery P; Vencovský J; Sylwestrzak A; Leszczyński P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
Ann Rheum Dis; 2017 Jan; 76(1):51-57. PubMed ID: 26150601
[TBL] [Abstract][Full Text] [Related]
23. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data.
Atzeni F; Gerratana E; Bongiovanni S; Talotta R; Miceli G; Salaffi F; Sarzi-Puttini P
Isr Med Assoc J; 2021 Jun; 23(6):344-349. PubMed ID: 34155846
[TBL] [Abstract][Full Text] [Related]
25. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B; Loft AG; Omerovic E; Hendricks O; Linauskas A; Espesen J; Danebod K; Jensen DV; Nordin H; Dalgaard EB; Chrysidis S; Kristensen S; Raun JL; Lindegaard H; Manilo N; Jakobsen SH; Hansen IMJ; Dalsgaard Pedersen D; Sørensen IJ; Andersen LS; Grydehøj J; Mehnert F; Krogh NS; Hetland ML
Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
[TBL] [Abstract][Full Text] [Related]
26. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.
Bruni C; Gentileschi S; Pacini G; Baldi C; Capassoni M; Tofani L; Bardelli M; Cometi L; Cantarini L; Nacci F; Vietri M; Bartoli F; Fiori G; Frediani B; Matucci-Cerinic M
Ther Adv Musculoskelet Dis; 2020; 12():1759720X20964031. PubMed ID: 33133246
[TBL] [Abstract][Full Text] [Related]
27. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
[TBL] [Abstract][Full Text] [Related]
28. LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis.
Song YW; Park YB; Kim J
Expert Opin Biol Ther; 2021 Jan; 21(1):1-8. PubMed ID: 31801395
[No Abstract] [Full Text] [Related]
29. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
Bae SC; Kim J; Choe JY; Park W; Lee SH; Park YB; Shim SC; Lee SS; Sung YK; Choi CB; Lee SR; Park H; Ahn Y;
Ann Rheum Dis; 2017 Jan; 76(1):65-71. PubMed ID: 26905864
[TBL] [Abstract][Full Text] [Related]
30. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
[TBL] [Abstract][Full Text] [Related]
31. Non-medical switching from reference to biosimilar etanercept - no evidence for nocebo effect: a retrospective analysis of real-life data.
Kiltz U; Pudelko JC; Tsiami S; Baraliakos X; Braun J
Clin Exp Rheumatol; 2021; 39(6):1345-1351. PubMed ID: 33427615
[TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
[TBL] [Abstract][Full Text] [Related]
33. Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort.
Kawakami T; Masui S; Onishi A; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Shimada T; Nakagawa S; Matsuda S; Morinobu A; Terada T; Yonezawa A
Mod Rheumatol; 2024 Mar; ():. PubMed ID: 38516944
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness, safety and economic analysis of Benepali in clinical practice.
Rojas-Giménez M; Mena-Vázquez N; Romero-Barco CM; Manrique-Arija S; Ureña-Garnica I; Diaz-Cordovés G; Jiménez-Núñez FG; Fernández-Nebro A
Reumatol Clin (Engl Ed); 2021 Dec; 17(10):588-594. PubMed ID: 34823826
[TBL] [Abstract][Full Text] [Related]
35. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
36. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H; Hendricks O; Jensen DV; Loft AG; Pedersen JK; Just SA; Danebod K; Munk HL; Kristensen S; Manilo N; Colic A; Linauskas A; Thygesen PH; Christensen LB; Kalisz MH; Lomborg N; Chrysidis S; Raun JL; Andersen M; Mehnert F; Krogh NS; Hetland ML; Glintborg B
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study.
Gharibdoost F; Salari AH; Salesi M; Ebrahimi Chaharom F; Mottaghi P; Hosseini M; Sahebari M; Nazarinia M; Mirfeizi Z; Shakibi M; Moussavi H; Karimifar M; Mowla K; Karimzadeh H; Anjidani N; Jamshidi A
Adv Ther; 2021 Feb; 38(2):1290-1300. PubMed ID: 33432540
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
Park MC; Matsuno H; Kim J; Park SH; Lee SH; Park YB; Lee YJ; Lee SI; Park W; Sheen DH; Choe JY; Choi CB; Hong SJ; Suh CH; Lee SS; Cha HS; Yoo B; Hur JW; Kim GT; Yoo WH; Baek HJ; Shin K; Shim SC; Yang HI; Kim HA; Park KS; Choi IA; Lee J; Tomomitsu M; Shin S; Lee J; Song YW
Arthritis Res Ther; 2019 May; 21(1):122. PubMed ID: 31113455
[TBL] [Abstract][Full Text] [Related]
39. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
[TBL] [Abstract][Full Text] [Related]
40. Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment.
Conigliaro P; Triggianese P; Perricone C; Chimenti MS; Di Muzio G; Ballanti E; Guarino MD; Kroegler B; Gigliucci G; Grelli S; Perricone R
Clin Exp Immunol; 2014 Jul; 177(1):234-43. PubMed ID: 24666401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
